Anthony G. Quinn Acquires 31,905 Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Stock

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CEO Anthony G. Quinn purchased 31,905 shares of Aeglea Bio Therapeutics stock in a transaction dated Friday, June 14th. The stock was bought at an average price of $6.16 per share, for a total transaction of $196,534.80. Following the completion of the transaction, the chief executive officer now directly owns 333,955 shares in the company, valued at $2,057,162.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of NASDAQ:AGLE traded up $0.03 during midday trading on Friday, hitting $6.18. The company had a trading volume of 125,122 shares, compared to its average volume of 174,363. Aeglea Bio Therapeutics Inc has a 12 month low of $5.99 and a 12 month high of $11.37. The firm has a market capitalization of $177.43 million, a P/E ratio of -2.90 and a beta of 0.96.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.04). On average, sell-side analysts predict that Aeglea Bio Therapeutics Inc will post -2.14 earnings per share for the current year.

AGLE has been the topic of several recent research reports. JPMorgan Chase & Co. initiated coverage on Aeglea Bio Therapeutics in a research report on Thursday, March 21st. They issued an “overweight” rating and a $14.00 price target on the stock. ValuEngine lowered Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 9th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Aeglea Bio Therapeutics in a research report on Monday, June 3rd. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Aeglea Bio Therapeutics presently has a consensus rating of “Buy” and an average price target of $16.00.

Hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA bought a new position in Aeglea Bio Therapeutics during the first quarter worth about $32,000. Canada Pension Plan Investment Board bought a new position in Aeglea Bio Therapeutics during the fourth quarter worth about $37,000. JPMorgan Chase & Co. lifted its holdings in Aeglea Bio Therapeutics by 58.6% during the first quarter. JPMorgan Chase & Co. now owns 6,674 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 2,467 shares in the last quarter. Meeder Asset Management Inc. lifted its holdings in Aeglea Bio Therapeutics by 38.4% during the first quarter. Meeder Asset Management Inc. now owns 7,083 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,967 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in Aeglea Bio Therapeutics during the first quarter worth about $69,000. Hedge funds and other institutional investors own 68.48% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/06/14/anthony-g-quinn-acquires-31905-shares-of-aeglea-bio-therapeutics-inc-nasdaqagle-stock.html.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Recommended Story: Limitations of the P/E Growth ratio

Insider Buying and Selling by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.